SOPHiA GENETICS SA (SOPH)

Market Cap	217.87M
Revenue (ttm)	65.17M
Net Income (ttm)	-62.49M
Shares Out	66.83M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,672
Open	3.670
Previous Close	3.680
Day's Range	3.200 - 3.670
52-Week Range	2.700 - 6.280
Beta	1.01
Analysts	Strong Buy
Price Target	6.50 (+99.39%)
Earnings Date	Mar 4, 2025

About SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, Nor...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: SOPH
• Website: https://www.sophiagenetics.com

Financial Performance

In 2024, SOPHiA GENETICS's revenue was $65.17 million, an increase of 4.49% compared to the previous year's $62.37 million. Losses were -$62.49 million, -20.88% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 99.39% from the latest price.

Price Target

$6.5

(99.39% upside)

Analyst Consensus: Strong Buy